{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Nanotechnologie : Questions médicales les plus fréquentes",
"headline": "Nanotechnologie : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Nanotechnologie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-17",
"dateModified": "2025-05-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Nanotechnologie"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Miniaturisation",
"url": "https://questionsmedicales.fr/mesh/D008904",
"about": {
"@type": "MedicalCondition",
"name": "Miniaturisation",
"code": {
"@type": "MedicalCode",
"code": "D008904",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "J01.897.520"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Nanomédecine",
"alternateName": "Nanomedicine",
"url": "https://questionsmedicales.fr/mesh/D050997",
"about": {
"@type": "MedicalCondition",
"name": "Nanomédecine",
"code": {
"@type": "MedicalCode",
"code": "D050997",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "J01.897.520.600.600"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Nanomédecine théranostique",
"alternateName": "Theranostic Nanomedicine",
"url": "https://questionsmedicales.fr/mesh/D000068936",
"about": {
"@type": "MedicalCondition",
"name": "Nanomédecine théranostique",
"code": {
"@type": "MedicalCode",
"code": "D000068936",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "J01.897.520.600.600.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Nanotechnologie",
"alternateName": "Nanotechnology",
"code": {
"@type": "MedicalCode",
"code": "D036103",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kamel A Abd-Elsalam",
"url": "https://questionsmedicales.fr/author/Kamel%20A%20Abd-Elsalam",
"affiliation": {
"@type": "Organization",
"name": "Plant Pathology Research Institute, Agricultural Research Centre, Giza 12619, Egypt."
}
},
{
"@type": "Person",
"name": "Paul S Weiss",
"url": "https://questionsmedicales.fr/author/Paul%20S%20Weiss",
"affiliation": {
"@type": "Organization",
"name": "California NanoSystems Institute, Department of Chemistry & Biochemistry, Department of Bioengineering, and Department of Materials Science & Engineering, University of California, Los Angeles, Los Angeles, California 90095, United States."
}
},
{
"@type": "Person",
"name": "Piotr Grodzinski",
"url": "https://questionsmedicales.fr/author/Piotr%20Grodzinski",
"affiliation": {
"@type": "Organization",
"name": "Nanodelivery Systems and Devices Branch, Cancer Imaging Program, National Cancer Institute, Rockville, MD, United States."
}
},
{
"@type": "Person",
"name": "Vishnu D Rajput",
"url": "https://questionsmedicales.fr/author/Vishnu%20D%20Rajput",
"affiliation": {
"@type": "Organization",
"name": "Academy of Biology and Biotechnology, Southern Federal University, 344090 Rostov-on-Don, Russia."
}
},
{
"@type": "Person",
"name": "Tatiana Minkina",
"url": "https://questionsmedicales.fr/author/Tatiana%20Minkina",
"affiliation": {
"@type": "Organization",
"name": "Academy of Biology and Biotechnology, Southern Federal University, 344090 Rostov-on-Don, Russia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "New Multilocus Sequence Typing Scheme for Enterococcus faecium Based on Whole Genome Sequencing Data.",
"datePublished": "2023-06-12",
"url": "https://questionsmedicales.fr/article/37306567",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1128/spectrum.05107-22"
}
},
{
"@type": "ScholarlyArticle",
"name": "Molecular Characterization of Enterococcus faecium Clinical Isolates Harbouring erm (T) from an Italian Hospital.",
"datePublished": "2024-10-29",
"url": "https://questionsmedicales.fr/article/39472351",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00284-024-03968-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "A molecular study regarding the spread of vanA vancomycin-resistant Enterococcus faecium in a tertiary hospital in China.",
"datePublished": "2022-10-20",
"url": "https://questionsmedicales.fr/article/36273808",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jgar.2022.10.010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Flow cytometric detection of vancomycin-resistant Enterococcus faecium in urine using fluorescently labelled enterocin K1.",
"datePublished": "2023-07-06",
"url": "https://questionsmedicales.fr/article/37414859",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-38114-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Using Genomics To Investigate an Outbreak of Vancomycin-Resistant Enterococcus faecium ST78 at a Large Tertiary Hospital in Queensland.",
"datePublished": "2023-05-16",
"url": "https://questionsmedicales.fr/article/37191518",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1128/spectrum.04204-22"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Technologie, industrie et agriculture",
"item": "https://questionsmedicales.fr/mesh/D013676"
},
{
"@type": "ListItem",
"position": 3,
"name": "Technologie",
"item": "https://questionsmedicales.fr/mesh/D013672"
},
{
"@type": "ListItem",
"position": 4,
"name": "Miniaturisation",
"item": "https://questionsmedicales.fr/mesh/D008904"
},
{
"@type": "ListItem",
"position": 5,
"name": "Nanotechnologie",
"item": "https://questionsmedicales.fr/mesh/D036103"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Nanotechnologie - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Nanotechnologie",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Nanotechnologie",
"description": "Comment la nanotechnologie aide-t-elle au diagnostic médical ?\nQuels outils nanotechnologiques sont utilisés pour le diagnostic ?\nLa nanotechnologie peut-elle détecter des maladies précocement ?\nQuels types de maladies peuvent être diagnostiqués par nanotechnologie ?\nY a-t-il des risques associés au diagnostic par nanotechnologie ?",
"url": "https://questionsmedicales.fr/mesh/D036103?mesh_terms=Enterococcus+faecium&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Nanotechnologie",
"description": "La nanotechnologie peut-elle aider à prévenir des maladies ?\nQuels vaccins utilisent la nanotechnologie ?\nComment la nanotechnologie améliore-t-elle la prévention des infections ?\nLa nanotechnologie peut-elle réduire les épidémies ?\nQuels sont les défis de la prévention par nanotechnologie ?",
"url": "https://questionsmedicales.fr/mesh/D036103?mesh_terms=Enterococcus+faecium&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Nanotechnologie",
"description": "Comment la nanotechnologie est-elle utilisée dans les traitements ?\nQuels médicaments utilisent la nanotechnologie ?\nLa nanotechnologie améliore-t-elle l'efficacité des traitements ?\nQuels sont les avantages des traitements nanotechnologiques ?\nY a-t-il des effets secondaires des traitements par nanotechnologie ?",
"url": "https://questionsmedicales.fr/mesh/D036103?mesh_terms=Enterococcus+faecium&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Nanotechnologie",
"description": "Quelles complications peuvent survenir avec la nanotechnologie ?\nLes nanoparticules peuvent-elles s'accumuler dans le corps ?\nComment évaluer les risques des traitements par nanotechnologie ?\nY a-t-il des effets à long terme des traitements nanotechnologiques ?\nComment minimiser les complications liées à la nanotechnologie ?",
"url": "https://questionsmedicales.fr/mesh/D036103?mesh_terms=Enterococcus+faecium&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Nanotechnologie",
"description": "Quels sont les facteurs de risque liés à l'utilisation de la nanotechnologie ?\nLes personnes allergiques sont-elles à risque avec la nanotechnologie ?\nLes enfants sont-ils plus à risque avec la nanotechnologie ?\nComment la génétique influence-t-elle les risques liés à la nanotechnologie ?\nLes personnes âgées sont-elles plus vulnérables à la nanotechnologie ?",
"url": "https://questionsmedicales.fr/mesh/D036103?mesh_terms=Enterococcus+faecium&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la nanotechnologie aide-t-elle au diagnostic médical ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet des diagnostics plus précis grâce à des capteurs et des agents de contraste à l'échelle nanométrique."
}
},
{
"@type": "Question",
"name": "Quels outils nanotechnologiques sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des nanoparticules et des nanocapteurs sont utilisés pour détecter des biomarqueurs spécifiques."
}
},
{
"@type": "Question",
"name": "La nanotechnologie peut-elle détecter des maladies précocement ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet de détecter des maladies à un stade précoce grâce à une sensibilité accrue."
}
},
{
"@type": "Question",
"name": "Quels types de maladies peuvent être diagnostiqués par nanotechnologie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est utilisée pour diagnostiquer le cancer, les maladies cardiovasculaires et infectieuses."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques associés au diagnostic par nanotechnologie ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des réactions allergiques ou des effets inconnus des nanoparticules."
}
},
{
"@type": "Question",
"name": "La nanotechnologie peut-elle aider à prévenir des maladies ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet de développer des vaccins plus efficaces et des systèmes de délivrance ciblée."
}
},
{
"@type": "Question",
"name": "Quels vaccins utilisent la nanotechnologie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccins contre le cancer et des vaccins à ARNm utilisent des nanoparticules pour l'administration."
}
},
{
"@type": "Question",
"name": "Comment la nanotechnologie améliore-t-elle la prévention des infections ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de créer des surfaces antimicrobiennes et des dispositifs de libération de médicaments."
}
},
{
"@type": "Question",
"name": "La nanotechnologie peut-elle réduire les épidémies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en développant des diagnostics rapides et des traitements ciblés pour les agents pathogènes."
}
},
{
"@type": "Question",
"name": "Quels sont les défis de la prévention par nanotechnologie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les défis incluent la réglementation, la sécurité et l'acceptation par le public."
}
},
{
"@type": "Question",
"name": "Comment la nanotechnologie est-elle utilisée dans les traitements ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de cibler les cellules malades avec des médicaments encapsulés dans des nanoparticules."
}
},
{
"@type": "Question",
"name": "Quels médicaments utilisent la nanotechnologie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des chimiothérapies et des médicaments anti-inflammatoires sont formulés avec des nanoparticules."
}
},
{
"@type": "Question",
"name": "La nanotechnologie améliore-t-elle l'efficacité des traitements ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle augmente l'efficacité en ciblant directement les cellules malades et en réduisant les effets secondaires."
}
},
{
"@type": "Question",
"name": "Quels sont les avantages des traitements nanotechnologiques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils offrent une meilleure biodisponibilité et une réduction des doses nécessaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires des traitements par nanotechnologie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent survenir, mais ils sont souvent moindres que ceux des traitements traditionnels."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la nanotechnologie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des réactions immunitaires et des toxicités potentielles des nanoparticules."
}
},
{
"@type": "Question",
"name": "Les nanoparticules peuvent-elles s'accumuler dans le corps ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines nanoparticules peuvent s'accumuler dans les organes, entraînant des effets indésirables."
}
},
{
"@type": "Question",
"name": "Comment évaluer les risques des traitements par nanotechnologie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études précliniques et cliniques sont nécessaires pour évaluer la sécurité et l'efficacité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets à long terme des traitements nanotechnologiques ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme sont encore en cours d'étude, nécessitant une surveillance continue."
}
},
{
"@type": "Question",
"name": "Comment minimiser les complications liées à la nanotechnologie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "En optimisant la formulation des nanoparticules et en surveillant les patients de près."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque liés à l'utilisation de la nanotechnologie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition professionnelle et l'utilisation non réglementée de nanoparticules."
}
},
{
"@type": "Question",
"name": "Les personnes allergiques sont-elles à risque avec la nanotechnologie ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes allergiques peuvent avoir des réactions indésirables aux nanoparticules."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus à risque avec la nanotechnologie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent être plus sensibles aux effets des nanoparticules en raison de leur développement."
}
},
{
"@type": "Question",
"name": "Comment la génétique influence-t-elle les risques liés à la nanotechnologie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des variations génétiques peuvent affecter la réponse aux nanoparticules et leur toxicité."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus vulnérables à la nanotechnologie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir une réponse immunitaire altérée, augmentant les risques."
}
}
]
}
]
}
The MLST scheme currently used for Enterococcus faecium typing was designed in 2002 and is based on putative gene functions and Enterococcus faecalis gene sequences available at that time. As a result...
Vancomycin-resistant enterococci (VRE) are one of the most important bacterial causes of healthcare-associated infections (HAIs). In China, the detection rate of VRE Enterococcus faecium (VREfm) is lo...
The characteristics of E. faecium strains isolated from 89 patients with HAIs, including antibiotic susceptibility and virulence genes, were analyzed. This study analyzed 50 E. faecium strains isolate...
Twenty-seven E. faecium isolates containing the vanA gene were identified as VREfm in 89 non-duplicate E. faecium isolates. The major clonal VREfm strains that persisted from 2013-2015 were CT1/ST78/P...
In this study, we report the spread caused by vanA vancomycin-resistant E. faecium strains of different cluster types with the same type of transposon in a tertiary hospital. Our literature review rev...
A urinary tract infection (UTI) occurs when bacteria enter and multiply in the urinary system. The infection is most often caused by enteric bacteria that normally live in the gut, which include Enter...
To investigate an outbreak of vancomycin-resistant Enterococcus faecium (VREfm) sequence type 78 (ST78) in a large tertiary Australian hospital. A collection of 63 VREfm ST78 isolates, identified duri...
Enterococcus faecium (E. faecium) is a member of symbiotic lactic acid bacteria in gastrointestinal tract and it was successfully used to treat diarrhea cases in humans. For a lactobacteria to survive...
To assess the acquired thermostability of PYK of ALE strain using in silico methods....
First, we predicted and assessed tertiary structures of our proteins using SWISS-MODEL homology modelling server. Second, we then applied molecular dynamics (MD) simulation to simulate and assess mult...
We collected the results of MD simulation at four temperature points: 300, 340, 350 and 400 K. Our results showed that the protein demonstrated increased stability at 340 and 350 K....
Results of these study suggest that PYK of ALE enhanced strain of E. faecium demonstrates overall better stability at elevated temperatures compared to that of WT strain....
Detection of vancomycin-resistant Enterococcus faecium (VRE) is hampered by low sensitivity of rectal swab cultures. This study aimed to define the number of screening cultures needed to increase sens...
Enterococcus faecium is a major cause of community and hospital-acquired infections. Due to limited options for infection with fluoroquinolones-resistant Enterococci, novel therapeutics are urgently n...
A total of 88 isolates of E. faecium from clinical specimens were studied from August 2017 to September 2018. Conventional phenotypic and molecular methods characterized all the isolates. Standard sus...
The highest antibiotic resistance rate among E. faecium isolates was related to ciprofloxacin (96.8%), levofloxacin (94.3%), and imipenem (90.9%), respectively. The highest frequency of efflux pump de...
Efflux pump inhibitor genes efrAB, efmA, and emeA are common among the E. faecium clinical isolates. Our results supported the administration of thioridazine, as an efflux pump inhibitor, in fluoroqui...
It is unclear whether the poor outcome of patients with severe vancomycin-resistant enterococci (VRE) infection is attributable to vancomycin resistance or to Enterococcus faecium (Efm), which predomi...
Retrospective study of a prospectively identified cohort from nationwide surveillance. A cohort of consecutive, nonduplicate episodes of monomicrobial bloodstream infections (BSIs) caused by Efm in 20...
A total of 241 Efm BSI episodes were included, of which 59 (24.5%) were VREfm. Patients with VREfm BSI were younger but had similar comorbidities to those with vancomycin-sensitive Efm (VSEfm) BSI. Mu...
In patients with Efm BSI, vancomycin resistance was independently associated with mortality....